The ureter, a vital tubular conduit responsible for transporting urine from the kidneys to the bladder, has remained an elusive component in lab-grown kidney models. Despite advancements in kidney organoid technology, the absence of a functional ureter has long hindered the ability to replicate the full physiological complexity and functionality of the urinary system. The inability to simulate urine flow and drainage has presented a significant barrier to the clinical translation of kidney organoids for transplantation.

To overcome this challenge, the team devised a sophisticated protocol to induce the differentiation of ureteral stromal progenitor cells from pluripotent stem cells. Utilizing these stromal progenitors in conjunction with ureteral epithelial progenitor cells—sourced either from mouse embryos or induced from pluripotent stem cells themselves—they engineered three-dimensional organoids that spontaneously self-organize into layered ureteral structures. Remarkably, these organoids exhibit peristaltic contractions, mimicking the rhythmic movements essential for urine propulsion observed in vivo.

This self-organization into a functional, three-layered ureteral architecture comprising stromal, epithelial, and muscle-like layers indicates the organoids’ potential to recapitulate the structural and physiological properties of natural ureters. The researchers documented rhythmic contractions resembling those of native urine flow, a feature never before demonstrated in stem cell-derived ureteral constructs. This functional mimicry suggests that the engineered ureters are not merely structural replicas but possess dynamic capabilities fundamental to their biological role.

Beyond structural and functional replication, the study also ventured into modeling congenital ureteral anomalies by introducing mutations in the TBX18 gene—a transcription factor crucial for ureter development. Organoids derived from TBX18-mutated cells displayed impaired development and morphological abnormalities, thereby establishing a novel platform for investigating the genetic underpinnings of urinary tract malformations. This disease modeling capacity provides an invaluable tool for exploring the pathogenesis of congenital disorders and assessing potential therapeutic interventions.

Professor Nishinakamura emphasized the transformative implications of this research, noting that integrating these ureter organoids with existing kidney organoids may finally fulfill the longstanding goal of producing transplantable kidneys capable of actual urine production and excretion. This synergy paves the way for regenerative therapies that do not merely replace kidney tissue but restore the comprehensive function of the entire urinary tract.

The creation of a functional ureter from pluripotent stem cells is a testament to the remarkable advances in developmental biology and stem cell technology. By recapitulating embryonic developmental pathways, the research team succeeded in coaxing pluripotent cells to differentiate into specialized progenitor populations and self-assemble into complex organ architectures. This bottom-up approach mirrors natural ontogeny and contrasts with previous methods that often relied on exogenous scaffolds or artificial constructs.

The methodology underpinning this breakthrough involved the careful orchestration of signaling pathways and microenvironmental cues to direct stem cell fate. By manipulating molecular gradients and timing differentiation stages precisely, the team generated stromal progenitors marked by specific lineage markers, such as TBX18, that are essential for ureter development. Combining these cells with epithelial progenitors allowed for the establishment of key cell-cell interactions vital for tissue maturation and organoid formation.

Importantly, the engineered ureter organoids demonstrated essential functional characteristics, including concentric smooth muscle-like layers responsible for contractility and an epithelial lining competent for barrier function and urine transport. The differentiation and maturation of these cell layers were validated through histological analyses and gene expression profiling, confirming their resemblance to natural ureteral tissue.

This milestone not only enhances the sophistication of kidney organoid models but also elevates the potential for their clinical application. Currently, kidney organoids—while capable of mimicking nephron structures—lack the ability to process and excrete urine effectively due to the absence of a ureter. The addition of functional ureters closes this gap, potentially enabling fully integrated renal organoids that replicate whole-organ physiology necessary for transplantation.

The success achieved by Kumamoto University’s team is part of the broader “International Leading Research: Creating A Kidney” project, an ambitious global initiative funded by the Japan Society for the Promotion of Science (JSPS) and other leading agencies. This consortium unites researchers worldwide to push the boundaries of organoid science, regenerative therapies, and organ transplantation, with a mission to overcome current organ shortages and improve patient outcomes.

The implications of this research extend beyond transplantation medicine. The ureter organoid system provides an unprecedented in vitro model for studying urinary tract development, physiology, and pathology. This platform could enable high-throughput screening for nephrotoxic drugs, investigation of urinary tract infections, and exploration of mechanisms underlying urinary tract obstructions and other diseases that currently lack robust experimental models.

Looking forward, challenges remain in scaling these organoids for clinical use, integrating them into vascularized systems, and ensuring long-term viability and functionality post-transplantation. Nevertheless, this study constitutes a crucial first step by demonstrating the feasibility of generating functional ureteral tissue from pluripotent stem cells, setting the stage for future breakthroughs that may revolutionize kidney regenerative medicine.

The convergence of stem cell biology, organoid technology, and developmental genetics encapsulated in this research highlights an era of unprecedented potential for personalized and regenerative therapies. Through meticulous engineering of cellular components and microenvironments, the longstanding dream of bioengineered, fully functional, transplantable kidneys incorporating complex urinary tract structures edges closer to realization.

Subject of Research: Cells

Article Title: In vitro generation of a ureteral organoid from pluripotent stem cells

News Publication Date: 20-Jun-2025

References:
Ibi et al., Nature Communications, DOI: 10.1038/s41467-025-60693-6

Image Credits: Ibi et al.

Keywords: Kidney, Pluripotent stem cells, Stroma, Somatic cells, Mesoderm, Progenitor cells, Organoids, Epithelial cells, Urine

At its core, CryoZoo functions as an extensive biobank specializing in animal cell lines, meticulously collecting, cataloguing, and preserving over 2,000 samples deriving from nearly 300 species including mammals, reptiles, amphibians, and fish. It transcends traditional cryopreservation by incorporating comprehensive molecular characterizations such as whole-genome sequencing, transcriptome profiling, and chromosomal mapping. These techniques generate rich datasets that not only safeguard genetic material but also provide invaluable insights into gene expression patterns and genomic architecture. This molecular repository is accessible to the global scientific community through approval by CryoZoo’s ethical and scientific review board, boosting international collaborative research efforts aimed at understanding and preserving biodiversity.

One of CryoZoo’s most groundbreaking initiatives focuses on the generation of induced pluripotent stem cells (iPSCs) derived from wild animal species. iPSCs, which are reprogrammed somatic cells capable of differentiating into any cell type, are pivotal for studying biodiversity at a functional genomic level without the ethical and practical challenges associated with live animal experimentation. Historically, the derivation of iPSCs has been predominantly successful in species genetically proximate to humans, primarily certain primates. The CryoZoo project now aims to expand this frontier by utilizing machine learning and artificial intelligence to decode and tailor the gene regulatory networks that govern cell reprogramming across a wider phylogenetic spectrum.

This AI-driven approach allows researchers to analyze gene activity patterns integral to cellular identity and plasticity, thereby formulating customized gene cocktails necessary for inducing pluripotency in diverse species. This technical advancement holds the promise of unlocking regenerative and reproductive capabilities in species ranging from dolphins to giraffes, whose genetic rewiring requirements for reprogramming are not currently understood. The fresh funding awarded by Revive & Restore, a leading nonprofit organization promoting biotechnology integration within conservation, facilitates this transformative research. Notably, among fifty global submissions, only three projects received this prestigious support, underscoring CryoZoo’s exceptional innovation and impact.

CryoZoo’s strategic collaboration with Spanish zoos, all members of the Iberian Association of Zoos and Aquariums (AIZA), along with specimens provided by the Natural Science Museum of Barcelona, enriches its biological sample diversity. This network ensures ethical sourcing of tissues and broadens the genetic representation within its biobank, crucial for generating comparative genomic data critical to evolutionary biology, species-specific disease mechanisms, and conservation-induced phenotypic plasticity. The integration of these diverse biological resources with advanced omics and computational biology harnesses a new paradigm of conservation research—where technology and ecology intersect to address species decline.

Recognizing the severity of the extinction crisis—currently threatening over 47,000 species globally as reported by the International Union for Conservation of Nature (IUCN)—CryoZoo’s work transcends mere preservation. It shapes a proactive scientific framework that anticipates conservation needs by enabling detailed biological characterization and practical regenerative solutions in the future. This vision aligns with the global conservation community’s shift towards genetic rescue and innovative conservation interventions that include disease resistance engineering, adaptive capacity enhancement, and potential synthetic biology applications.

Moreover, CryoZoo stands among the few global leaders influencing the IUCN’s Animal Biobanking Working Group, placing it alongside established institutions like the San Diego Zoo. Its contributions extend beyond sample storage to shaping policies and practices related to genetic resource use, ethical biobanking, and the deployment of stem cell technologies in wildlife.

The technical prowess of CryoZoo is embodied in its repository of over 350 cryopreserved cell lines, including seven successfully reprogrammed iPSC lines, 37 karyotypes reflecting chromosomal compositions across species, and genome sequences from 163 animal species. This foundational infrastructure enables the research community to conduct intricate genetic studies, investigate cellular mechanisms underlying species-specific traits, and explore novel pathways to mitigate species decline.

Integral to CryoZoo’s scientific leadership is the strategic use of transcriptomics, allowing the identification of active gene networks during the cellular conversion process. This molecular insight is key to understanding the epigenetic and gene regulatory landscapes that must be manipulated for successful iPSC generation, highlighting how each species’ unique evolutionary context shapes cellular reprogramming capacity. By decoding these complex molecular signatures, CryoZoo not only advances stem cell biology in wildlife but also develops frameworks potentially applicable to human regenerative medicine and comparative genomics.

The project also exemplifies the growing role of interdisciplinary approaches in wildlife conservation, merging molecular biology, bioinformatics, veterinary science, and ethical governance. CryoZoo operates within the Barcelona Biomedical Research Park (PRBB), leveraging state-of-the-art facilities and expertise. It also integrates within UPF’s Planetary Wellbeing initiative and EMBL’s Planetary Biology Transversal Theme—both emphasizing the sustainable interaction between human activity and biodiversity through scientific innovation.

Revive & Restore’s competitive grant, awarded in December 2024, marks a pivotal moment for CryoZoo, significantly bolstering its capacity to scale molecular phenotyping and stem cell reprogramming across taxonomically diverse species. This collaboration will likely catalyze the development of new conservation biotechnologies, stimulating broader adoption of cellular reprogramming techniques for wildlife disease research, recrudescence of endangered species, and long-term ecosystem resilience strategies in the face of climate change and habitat disruption.

In summary, the Barcelona CryoZoo is not just preserving cells: it is preserving the blueprint of life itself to empower a future where endangered species can be studied deeply, conserved effectively, and potentially restored through molecular and cellular sciences. Its integration of cryopreservation, genomics, stem cell technology, and computational biology positions it at the vanguard of conservation science, epitomizing how multidisciplinary innovation can address one of humanity’s greatest challenges—biodiversity loss.

Subject of Research: Conservation biology utilizing induced pluripotent stem cell technology and molecular biobanking for endangered animal species.

Article Title: (Not explicitly provided in the source content)

News Publication Date: December 2024 (based on Revive & Restore grant announcement)

Web References:

• https://cryozoo.org
• https://reviverestore.org/
• https://zoobarcelona.cat/en/foundation/barcelona-zoo-foundation?language=en
• https://www.upf.edu/web/centre-planetary-wellbeing/
• https://www.embl.org/barcelona
• https://museuciencies.cat/es/

References: Not specified in the original content.

Image Credits: Barcelona Zoo/UPF/Creative Team EMBL

Keywords: Evolutionary biology, stem cell reprogramming, biodiversity conservation, cryopreservation, induced pluripotent stem cells, genomics, transcriptomics, cellular reprogramming, molecular biobanking, endangered species, wildlife conservation, artificial intelligence.

Diabetes, a condition affecting over 800 million people worldwide, represents a mounting global health crisis with significant morbidity. Central to its pathology is the dysregulation of blood glucose homeostasis, chiefly governed by the interplay between insulin-secreting beta cells and glucagon-secreting alpha cells in the pancreas. While beta cells have long been the focus of scientific inquiry due to their direct role in lowering blood sugar, growing evidence points to alpha cells as equally pivotal in maintaining the delicate balance required for metabolic equilibrium.

The pancreas houses these two endocrine cell types, which exert opposing effects on circulating glucose levels. Beta cells respond to hyperglycemia by releasing insulin, a hormone critical for glucose uptake and storage. Alpha cells, however, serve as a counter-regulatory force; their secretion of glucagon elevates blood glucose by stimulating hepatic glucose production. Maintaining a precise ratio and function of these cells ensures glucose homeostasis—a process that is profoundly disrupted in diabetic patients.

Despite the recognized importance of alpha cells, research models to study their dysfunction have remained limited due to difficulties in isolating and culturing these cells in vitro. The pioneering work from Quinn Peterson and colleagues addresses this challenge by successfully differentiating human alpha cells from pluripotent stem cells. These stem cell-derived alpha cells mimic their natural counterparts not only morphologically but also functionally, displaying comparable secretion profiles of glucagon in response to physiological cues.

Crucially, when exposed to conditions replicating a diabetic microenvironment—characterized by elevated glucose and other metabolic stressors—the stem cell-derived alpha cells exhibited hallmark signs of diabetic alpha cell dysfunction. This included increased glucagon secretion and altered gene expression patterns consistent with pathological states observed in diabetic patients. This ability to model diabetic alpha cell dysregulation ex vivo marks a significant step forward for diabetes research, as it enables the detailed mechanistic study of alpha cell pathology.

In addition to providing a window into the pathogenesis of diabetes, the new model serves as an invaluable platform for pharmaceutical screening. The study notably demonstrated that treatment with Sunitinib, an FDA-approved tyrosine kinase inhibitor commonly used in oncology, could reverse the aberrant glucagon secretion patterns in these dysfunctional alpha cells. This finding raises the prospect of repurposing existing drugs to target alpha cell abnormalities in diabetes—a therapeutic angle that has garnered little attention until now.

Understanding the intricate signaling pathways and gene regulatory networks that govern alpha cell identity and function remains a critical pursuit in diabetes biology. Stem cell-derived alpha cells offer researchers the prospect of manipulating genetic and epigenetic factors in a controlled environment to unravel these complexities. Future studies leveraging this model may uncover novel molecular targets for the development of alpha cell–specific therapeutics.

The implications extend beyond basic science, with the potential to influence clinical approaches to diabetes management. Current therapies predominantly focus on insulin replacement or sensitization, often neglecting the pathological hyperglucagonemia that exacerbates hyperglycemia. A deeper grasp of alpha cell biology and the means to correct its dysfunction could lead to more comprehensive regimens that tackle diabetes from multiple cellular angles, reducing complications and improving long-term outcomes.

Moreover, this advancement aligns with the broader vision of regenerative medicine, wherein stem cell technologies could eventually enable the replacement or restoration of damaged pancreatic cell populations in patients. By refining protocols for generating functional alpha cells, researchers move closer to the goal of creating implantable islet organoids or cell therapies capable of restoring endogenous glucose regulation.

Importantly, the techniques developed by Peterson’s team demonstrate scalability and reproducibility—key factors that will facilitate widespread adoption of this model in laboratories worldwide. This democratization of alpha cell research tools promises to accelerate discoveries across the scientific community, fostering collaborations and cross-disciplinary investigations into diabetes and metabolic diseases.

This work also underscores the essential balance in pancreatic islet biology, where disruption in one cell type’s function can have cascading effects on the entire endocrine system. The reciprocal dynamics between alpha and beta cells, once only hypothesized from indirect evidence, can now be experimentally interrogated using co-culture systems incorporating stem cell-derived populations, enhancing our understanding of intra-islet communication.

In an era where the prevalence of diabetes continues its relentless rise, research innovations like this offer hope, not just for better treatment, but for unraveling the fundamental biology underlying the disease. The convergence of stem cell biology, molecular endocrinology, and pharmacology in this research sets a precedent for integrative approaches needed to tackle complex chronic diseases.

As this research is disseminated through high-impact journals and shared across scientific networks, it will undoubtedly inspire further inquiries and new lines of investigation into the multifaceted roles of pancreatic alpha cells. The journey from stem cell differentiation to clinical application is long, but with such robust foundational studies, the future of diabetes research and treatment appears ever more plausible and promising.

Subject of Research: Human pancreatic alpha cells derived from stem cells to study diabetic dysfunction
Article Title: Generation of human stem cell-derived alpha cells to model diabetic alpha cell dysfunction
News Publication Date: 8-May-2025
Web References: https://www.cell.com/stem-cell-reports/fulltext/S2213-6711(25)00108-0
References: DOI: 10.1016/j.stemcr.2025.102504
Image Credits: Islet Engineering and Replacement Laboratory, Mayo Clinic
Keywords: Stem cell research, pancreatic alpha cells, diabetes, glucagon secretion, beta cells, regenerative medicine, Sunitinib, glucose homeostasis

The partnership between Stem Cell Reports and the BaCell 3D conference reflects a mutual commitment to enhance and facilitate collaborative efforts among various stakeholders in this rapidly evolving scientific field. By focusing on high-quality original research, this collaboration aims to generate a wealth of knowledge that can effectively bridge the gap between fundamental and clinical research. The journal encourages submissions that showcase transformative discoveries capable of reshaping the landscape of regenerative medicine.

At the heart of this initiative lies the overarching goal of fostering innovation through shared insights and discoveries. BaCell 3D is set to gather prominent thought leaders from around the globe, offering an exceptional platform to discuss cutting-edge innovations in organoid technology and advanced multicellular systems. Researchers and industry experts will be able to engage in meaningful dialogues, exchange ideas, and explore potential collaborations that could accelerate advancements in stem cell biology and its applications.

Additionally, as the official conference journal, Stem Cell Reports is uniquely positioned to spotlight pivotal studies that emerge from the BaCell 3D conference. This journal’s commitment to publishing impactful research aligns seamlessly with the objectives of the conference, highlighting significant breakthroughs that may redefine our understanding of multicellular systems and regenerative medicine. Attendees will have access to the latest research findings, creating opportunities to learn and discuss new publishing avenues with the journal.

The collaboration also extends into the digital sphere through a special scientific webinar organized alongside the BaCell 3D conference, focusing on the accomplishments of the conference’s early career award winners. This webinar aims to showcase the innovative research presented during the conference, ensuring that the broader scientific community remains informed and engaged. Participants will have a chance to interact with awardees and delve deeper into discussions surrounding their groundbreaking work.

With its dedicated focus on open-access publishing, Stem Cell Reports serves not only as a journal but also as a conduit for vital information dissemination within the scientific community. Its partnership with the International Society for Stem Cell Research (ISSCR) underscores a shared dedication to advancing scientific knowledge and fostering an environment conducive to collaboration. ISSCR’s extensive network, comprising nearly 5,000 members from over 80 countries, complements the journal’s mission, enhancing the collective pursuit of excellence in stem cell science.

The BaCell 3D conference represents a unique opportunity for networking, collaborative exploration, and the exchange of knowledge among researchers. In this context, the role of Stem Cell Reports becomes increasingly significant as it underscores the importance of multidisciplinary collaboration in overcoming the challenges faced in research and translating discoveries into clinical practice. The potential implications of advancements in organoid technology and multicellular systems cannot be overstated, and collective efforts are crucial to harnessing these innovations effectively.

The convergence of academic and industry perspectives at the BaCell 3D conference will provide a fertile ground for discussions that could lead to the discovery of novel approaches and methodologies in stem cell research. By focusing on facilitating interdisciplinary connections, the conference aims to inspire new ideas that leverage the strengths of both realms, ultimately accelerating the development of applications for organoids in biomedical research.

As the journey toward the 2025 conference unfolds, the anticipation builds around the innovations and insights that will emerge from this gathering of leading experts. The collaboration between Stem Cell Reports and BaCell 3D signifies a pivotal moment in the field, aimed at creating an inclusive platform where groundbreaking research can thrive and be recognized globally.

Researchers aiming to participate in this transformative dialogue are encouraged to explore the submission guidelines provided by Stem Cell Reports, ensuring their contributions are aligned with the ongoing pursuit of groundbreaking research in stem cell biology. It is vital for the scientific community to remain engaged and proactive, as advancements in this field hold significant promise for future breakthroughs that can greatly enhance human health and well-being.

In conclusion, the partnership between Stem Cell Reports and the BaCell 3D conference not only enriches the dialogue around stem cell research but also fosters an environment replete with opportunities for collaboration and innovation. The potential for developing next-generation therapies through insights gained from this collaboration could pave the way for monumental progress in regenerative medicine, making a lasting impact across the global scientific landscape.

Subject of Research: Stem Cell Biology and Organoid Technology
Article Title: Stem Cell Reports Joins Forces with BaCell 3D Conference as Official Journal
News Publication Date: [Insert Date]
Web References: http://www.bacell3d.com/
References: https://www.cell.com/stem-cell-reports/home, https://www.isscr.org/
Image Credits: Stem Cell Reports and Cell Press

Keywords: Stem cell research, Scientific journals, Clinical research, Discovery research, Industrial research, Organoids, Open access, Scientific collaboration, Clinical studies.